Effect of lisdexamfetamine dimesylate on functional impairment in children and adolescents with ADHD - 09/07/12
Doi : 10.1016/j.neurenf.2012.05.306
C. Soutullo a, ⁎, T. Banaschewski b, M. Lecendreux c, M. Johnson d, A. Zuddas e, R. Bloomfield f, P. Hodgkins g, L.A. Squires h, D.R. Coghill i
a Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University of Navarra Clinic, Pamplona, Spain
b Child and adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
c Pediatric Sleep Center, CHU Robert-Debré, Paris, France
d Child Neuropsychiatry Unit, Queen Silvia Children’s Hospital, Gothenburg, Sweden
e Centre for Pharmacological Therapies in Children and Adolescent Neuropsychiatry, Department Of Neuroscience, University of Cagliari, Cagliari, Italy
f Shire Pharmaceutical Development Ltd, Basingstoke, UK
g Shire Pharmaceuticals LLC, Wayne, USA
h Shire Development LLC, Wayne, USA
i Division of Neuroscience, Ninewells Hospital, Dundee, UK
Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
© 2012
Publié par Elsevier Masson SAS.
Vol 60 - N° 5S
P. S76 - juillet 2012 Retour au numéro
Article précédent
- Duration of response of lisdexamfetamine dimesylate in children and adolescents with ADHD
- A. Zuddas, T. Banaschewski, M. Lecendreux, R.W. Dittmann, I. Hernández Otero, C. Anderson, R. Civil, N. Higgins, R. Bloomfield, L. Squires
- Health-related quality of life outcomes in children and adolescents with ADHD treated with lisdexamfetamine dimesylate
- T. Banaschewski, M. Johnson, A. Zuddas, C. Soutullo, P. Hodgkins, R. Bloomfield, L.A. Squires, D.R. Coghill
Bienvenue sur EM-consulte, la référence des professionnels de santé.